{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:10Z","timestamp":1753891930578,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We present the clinical course of a 4-year-old girl with neurofibromatosis type 1-associated, unresectable, symptomatic urinary bladder ganglioneuroma. She was initially trialed on sirolimus without response and subsequently responded to MEK inhibitor trametinib, with improvement clinically and radiographically over 10 months. This report broadens the repertoire of therapeutic strategies for MEK inhibition in diseases related to the MAPK pathway.<\/jats:p>","DOI":"10.3389\/fonc.2024.1433073","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:56:02Z","timestamp":1720760162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Treatment response of NF-1-associated bladder ganglioneuroma to trametinib"],"prefix":"10.3389","volume":"14","author":[{"given":"Marcus C. Y.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin K. F.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai-Fu","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Ming","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis T. L.","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony P. Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12123126","article-title":"Ganglioneuroma of the bladder in association with neurofibromatosis type 1","volume":"12","author":"Tarc\u0103","year":"2022","journal-title":"Diagnostics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.10.027","article-title":"Bladder ganglioneuroma in a 5-Year-old girl presenting with a urinary tract infection and hematuria: case report and review of the literature","volume":"85","author":"Hartman","year":"2015","journal-title":"Urology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5489\/cuaj.1491","article-title":"Ganglioneuroma with leiomyomatosis of the urinary bladder: a rare tumor causing frequent micturition and dysuria","volume":"8","author":"Qi","year":"2014","journal-title":"Can Urological Assoc J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5489\/cuaj.1160","article-title":"Composite paraganglioma-ganglioneuroma of the urinary bladder: a rare neoplasm causing hemodynamic crisis at tumour resection","volume":"3","author":"Chen","year":"2013","journal-title":"Can Urological Assoc J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/145076","article-title":"Neurofibromatosis type 1 with bladder involvement","volume":"2013","author":"\u00dcre","year":"2013","journal-title":"Case Rep Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1440-1827.2005.01875.x","article-title":"Composite paraganglioma-ganglioneuroma of the urinary bladder","volume":"55","author":"Usuda","year":"2005","journal-title":"Pathol Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1078\/0344-0338-00495","article-title":"Pigmented composite Paraganglioma-Ganglioneuroma of the urinary bladder","volume":"199","author":"Dundr","year":"2003","journal-title":"Pathol - Res Practice"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/BF02739697","article-title":"Composite paraganglioma-ganglioneuroma of the urinary bladder: A clinicopathologic, immunohistochemical, and UItrastructural study of a case and review of the literature","volume":"9","author":"Lam","year":"1998","journal-title":"Endocrine Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.02.019","article-title":"Diffuse ganglioneuromatosis and plexiform neurofibroma of the urinary bladder: report of a pediatric example and literature review","volume":"39","author":"Scheithauer","year":"2008","journal-title":"Hum Pathology"},{"key":"B10","article-title":"A rare and easily misdiagnosed tumor of the urinary bladder: primary composite pheochromocytoma","volume":"10","author":"Hu","year":"2017","journal-title":"Int J Clin Exp Pathology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2020.1856621","article-title":"Targeting ganglioneuromas with mTOR inhibitors","volume":"8","author":"Tao","year":"2021","journal-title":"Mol Cell Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005625","article-title":"Retrospective analysis of retroperitoneal-abdominal-pelvic ganglioneuromas: an international study by the transatlantic Australasian retroperitoneal sarcoma working group (TARPSWG)","volume":"278","author":"Noh","year":"2023","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","article-title":"NF1 tumor suppressor gene function: narrowing the GAP","volume":"104","author":"Cichowski","year":"2001","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080956","article-title":"Efficacy and Safety of trametinib in neurofibromatosis Type 1-Associated plexiform neurofibroma and Low-Grade glioma: A Systematic Review and Meta-Analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1433073\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:56:05Z","timestamp":1720760165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1433073\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":16,"alternative-id":["10.3389\/fonc.2024.1433073"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1433073","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"article-number":"1433073"}}